In this study, we presented evidence to demonstrate frequent genetic alterations in ATM and TP53 genes in most R/R patients with MCL, including those with intrinsic or acquired resistance to ibrutinib or CD19-targeted CAR T-cell therapy. Here, TP53 is linked to mantle cell lymphoma.